The three most studied weight loss peptides, compared side by side. Mechanism, efficacy, side effects, cost, and availability — using published clinical trial data, not marketing copy.
Research context only. This comparison is based on published clinical trial data for educational purposes. None of these compounds should be compared for personal use without physician oversight. Not medical advice.
All three compounds belong to the GLP-1 receptor agonist class — but they're meaningfully different drugs with different mechanisms, different track records, and very different development timelines.
One important caveat before diving in: these trials cannot be directly compared. They used different populations, different durations, different endpoints, and different titration schedules. The numbers give a directional picture — not a controlled head-to-head. With that said, the directional picture is pretty clear.
The simplest way to understand the difference between these three drugs is to count receptors.
| Drug | GLP-1 | GIP | Glucagon | Type |
|---|---|---|---|---|
| Semaglutide | ✅ | — | — | Single agonist |
| Tirzepatide | ✅ | ✅ | — | Dual agonist |
| Retatrutide | ✅ | ✅ | ✅ | Triple agonist |
The bottom line on mechanism: Each additional receptor adds another lever for weight loss. Semaglutide hits appetite. Tirzepatide hits appetite plus insulin handling. Retatrutide hits all of that plus forces your body to burn stored fat at a higher rate.
Here's a side-by-side of the pivotal trial results for each compound. Remember: different trial designs, durations, and populations.
| Metric | Semaglutide 2.4mg | Tirzepatide 15mg | Retatrutide 12mg |
|---|---|---|---|
| Trial | STEP 1 (Phase 3) | SURMOUNT-1 (Phase 3) | NCT04881760 (Phase 2) |
| Duration | 68 weeks | 72 weeks | 48 weeks |
| Population | Obesity, no T2D | Obesity, no T2D | Obesity, no T2D |
| Mean weight loss | ~14.9% | ~20.9% | ~24.2% |
| ≥5% weight loss | 83% | 91% | 100% |
| ≥10% weight loss | 66% | 80% | 96% |
| ≥15% weight loss | 48% | 67% | 83% |
| ≥20% weight loss | 30% | 50% | 62% |
| Curve plateaued? | Yes, ~week 52 | Yes, ~week 60 | No — still declining at wk 48 |
The most important row in that table isn't the headline number. It's the last one. Retatrutide's weight loss curve had not plateaued at week 48. Semaglutide and tirzepatide both level off — retatrutide hadn't. Phase 3 runs 96 weeks to find out where the ceiling actually is.
What this likely means: Retatrutide's eventual Phase 3 peak weight loss number will probably be higher than 24.2% — not lower. If the curve continues at the same rate through 96 weeks, the final number could approach 30%+ in the highest dose group. That would be an entirely new category of pharmaceutical weight loss.
All three drugs share the same core side effect profile — GI symptoms during dose escalation. The differences are in severity and in a few compound-specific findings.
| Side Effect | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Nausea | Common (~44%) | Moderate (~31%) | Common — similar to sema |
| Vomiting | Common (~24%) | Less common (~16%) | Present, dose-dependent |
| Diarrhea | Common (~30%) | Common (~23%) | Present |
| Constipation | Present | Present | Present |
| Discontinuation rate | ~7% GI-related | ~4–6% GI-related | ~16% at highest dose |
| Heart rate increase | Minor (+1–2 bpm) | Minor (+2–3 bpm) | Notable (+5+ bpm) |
| Thyroid concerns | ⚠️ Monitored | ⚠️ Monitored | ⚠️ Monitored |
| Pancreatitis risk | ⚠️ Low, monitored | ⚠️ Low, monitored | ⚠️ No signal yet |
Two things stand out in retatrutide's safety profile:
Worth remembering: Semaglutide's GI side effects were also considered severe when it first launched. As clinicians got better at titration protocols, real-world tolerability improved significantly. Retatrutide is earlier in that learning curve.
These drugs are increasingly being studied for benefits beyond the scale. Here's where the data currently stands:
| Outcome | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Cardiovascular benefit | ✅ Proven (SELECT trial) | Phase 3 ongoing | Phase 3 ongoing |
| T2D management | ✅ FDA approved for T2D | ✅ FDA approved for T2D | Phase 2 data positive |
| Liver fat reduction (NAFLD) | Positive data | Strong positive data | Expected, not yet confirmed |
| Blood pressure | Modest reduction | Modest reduction | Reduction observed |
| Triglycerides | Improved | Improved | Improved |
| Visceral fat specifically | General fat loss | General fat loss | Targeted visceral fat (glucagon) |
Semaglutide has the longest track record — it's the only one with a completed cardiovascular outcomes trial (SELECT), which showed a 20% reduction in major cardiovascular events in high-risk patients. That's a significant advantage in terms of evidence depth, even if retatrutide's mechanism is theoretically superior for weight loss.
Retatrutide's glucagon component may give it a specific advantage in targeting visceral adipose tissue — the deep abdominal fat most closely associated with metabolic disease and cardiovascular risk. This is an area of active research in Phase 3.
| Semaglutide | Tirzepatide | Retatrutide | |
|---|---|---|---|
| FDA Status | Approved (Wegovy/Ozempic) | Approved (Zepbound/Mounjaro) | Phase 3 — Not Approved |
| Prescription availability | Yes | Yes | No |
| Compounded versions | Yes (limited, post-shortage) | Yes (limited) | Research peptide only |
| Research availability | Yes — research peptide | Yes — research peptide | Yes — research peptide |
| Approx. retail Rx cost | $1,200–$1,500/mo (uninsured) | $1,000–$1,400/mo (uninsured) | N/A — not Rx approved |
| Research peptide cost | ~$40–80 per 10mg vial | ~$40–80 per 10mg vial | ~$60–120 per 10–30mg vial |
Semaglutide and tirzepatide have an obvious advantage: they're FDA-approved, prescribable, and covered (partially) by some insurance plans. For people who qualify and can get coverage, the prescription route is the only legitimate medical option.
Retatrutide isn't approved and isn't prescribable. For research purposes, it's available from research chemical suppliers with COA documentation.
Retatrutide wins on every weight loss metric in published trial data. Higher mean weight loss, higher percentage of responders, higher percentage reaching ≥20% loss, and a curve that hadn't plateaued at 48 weeks. If Phase 3 holds, it will likely be the most effective pharmaceutical weight loss intervention ever approved.
Semaglutide wins. It has Phase 3 completion, FDA approval, real-world prescribing data across millions of patients, and a completed cardiovascular outcomes trial. The evidence base is orders of magnitude deeper than retatrutide's Phase 2 data.
Tirzepatide currently sits in a compelling middle position — better efficacy than semaglutide (by roughly 5–6 percentage points), better tolerability, and FDA approved. For most patients who can access it, tirzepatide is the current standard of care.
The honest take: Retatrutide is the most exciting compound in this class by a significant margin. But "most exciting Phase 2 data" is not the same as "proven safe and effective for broad use." It may well get there — Phase 3 data will tell us. Until then, it remains in a research context.
| Category | Winner | Why |
|---|---|---|
| Raw efficacy | Retatrutide | 24.2% vs 21% vs 15% |
| Evidence base | Semaglutide | Phase 3, CV outcomes, years of Rx data |
| Tolerability | Tirzepatide | Lower GI discontinuation than both |
| Metabolic breadth | Retatrutide | Glucagon adds visceral fat targeting |
| Availability (medical) | Semaglutide / Tirzepatide | FDA approved, prescribable |
| Research access | All three | All available as research peptides |
COA-verified vendor pricing, titration charts, and reconstitution protocol in one place.
Retatrutide Complete Guide →